RYR1 Chromosome 19
Ryanodine receptor 1
Upload your DNA to see your personal genotypes for variants in RYR1.
What This Gene Does
This gene encodes a ryanodine receptor found in skeletal muscle. The encoded protein functions as a calcium release channel in the sarcoplasmic reticulum but also serves to connect the sarcoplasmic reticulum and transverse tubule. Mutations in this gene are associated with malignant hyperthermia susceptibility, central core disease, and minicore myopathy with external ophthalmoplegia. Alternatively spliced transcripts encoding different isoforms have been described. [provided by RefSeq, Jul 2008]
Gene Info
Gene Group
"Ryanodine receptors|Protein phosphatase 1 regulatory subunits"
Locus Type
gene with protein product
Location
19q13.2
Ensembl
ENSG00000196218
Associated Conditions (74)
Central core myopathy
RYR1-related disorder
King Denborough syndrome
desflurane response - Toxicity
halothane response - Toxicity
enflurane response - Toxicity
isoflurane response - Toxicity
methoxyflurane response - Toxicity
sevoflurane response - Toxicity
succinylcholine response - Toxicity
RYR1-related myopathy
Malignant hyperthermia
susceptibility to
1
Congenital multicore myopathy with external ophthalmoplegia
Malignant hyperthermia of anesthesia
Congenital myopathy with fiber type disproportion
Inborn genetic diseases
Congenital myopathy
Myopathy
+54 more conditions
Key Variants
RS118192124
Likely pathogenic; drug response
Central core myopathy, RYR1-related disorder, King Denborough syndrome
Drug Response
RS121918596
Likely pathogenic; drug response
Malignant hyperthermia, susceptibility to, 1
Drug Response
RS193922748
Likely pathogenic; drug response
RYR1-related disorder, sevoflurane response - Toxicity, Malignant hyperthermia
Drug Response
RS193922762
Likely pathogenic; drug response
Malignant hyperthermia, susceptibility to, 1
Drug Response
RS193922770
Likely pathogenic; drug response
RYR1-related disorder, desflurane response - Toxicity, halothane response - Toxicity
Drug Response
RS193922818
Likely pathogenic; drug response
RYR1-related disorder, Malignant hyperthermia, susceptibility to
Drug Response
RS193922832
Likely pathogenic; drug response
RYR1-related disorder, sevoflurane response - Toxicity, desflurane response - Toxicity
Drug Response
RS193922876
Likely pathogenic; drug response
desflurane response - Toxicity, enflurane response - Toxicity, succinylcholine response - Toxicity
Drug Response
RS193922878
Likely pathogenic; drug response
desflurane response - Toxicity, halothane response - Toxicity, isoflurane response - Toxicity
Drug Response
RS28933397
Likely pathogenic; drug response
Malignant hyperthermia, susceptibility to, 1
Drug Response
RS118192122
Pathogenic; drug response
Central core myopathy, Malignant hyperthermia, susceptibility to
Drug Response
RS118192161
Pathogenic; drug response
Malignant hyperthermia, susceptibility to, 1
Drug Response
All Variants (1315)
| RSID | Category | Clinical Significance | Conditions |
|---|---|---|---|
| RS118192124 | Drug Response | Likely pathogenic; drug response | Central core myopathy, RYR1-related disorder, King Denborough syndrome |
| RS121918596 | Drug Response | Likely pathogenic; drug response | Malignant hyperthermia, susceptibility to, 1 |
| RS193922748 | Drug Response | Likely pathogenic; drug response | RYR1-related disorder, sevoflurane response - Toxicity, Malignant hyperthermia |
| RS193922762 | Drug Response | Likely pathogenic; drug response | Malignant hyperthermia, susceptibility to, 1 |
| RS193922770 | Drug Response | Likely pathogenic; drug response | RYR1-related disorder, desflurane response - Toxicity, halothane response - Toxicity |
| RS193922818 | Drug Response | Likely pathogenic; drug response | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS193922832 | Drug Response | Likely pathogenic; drug response | RYR1-related disorder, sevoflurane response - Toxicity, desflurane response - Toxicity |
| RS193922876 | Drug Response | Likely pathogenic; drug response | desflurane response - Toxicity, enflurane response - Toxicity, succinylcholine response - Toxicity |
| RS193922878 | Drug Response | Likely pathogenic; drug response | desflurane response - Toxicity, halothane response - Toxicity, isoflurane response - Toxicity |
| RS28933397 | Drug Response | Likely pathogenic; drug response | Malignant hyperthermia, susceptibility to, 1 |
| RS118192122 | Drug Response | Pathogenic; drug response | Central core myopathy, Malignant hyperthermia, susceptibility to |
| RS118192161 | Drug Response | Pathogenic; drug response | Malignant hyperthermia, susceptibility to, 1 |
| RS121918593 | Drug Response | Pathogenic; drug response | Malignant hyperthermia, susceptibility to, 1 |
| RS121918595 | Drug Response | Pathogenic; drug response | Malignant hyperthermia, susceptibility to, 1 |
| RS193922747 | Drug Response | Pathogenic; drug response | Malignant hyperthermia, susceptibility to, 1 |
| RS193922753 | Drug Response | Pathogenic; drug response | Malignant hyperthermia, susceptibility to, 1 |
| RS193922764 | Drug Response | Pathogenic; drug response | Malignant hyperthermia of anesthesia, RYR1-related disorder, Inborn genetic diseases |
| RS193922768 | Drug Response | Pathogenic; drug response | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS193922802 | Drug Response | Pathogenic; drug response | Malignant hyperthermia, susceptibility to, 1 |
| RS193922803 | Drug Response | Pathogenic; drug response | Congenital multicore myopathy with external ophthalmoplegia, RYR1-related disorder, Malignant hyperthermia |
| RS193922843 | Drug Response | Pathogenic; drug response | isoflurane response - Toxicity, sevoflurane response - Toxicity, methoxyflurane response - Toxicity |
| RS118192116 | Drug Response | Uncertain significance; drug response | Central core myopathy, isoflurane response - Toxicity, sevoflurane response - Toxicity |
| RS118192167 | Drug Response | Uncertain significance; drug response | Central core myopathy, Malignant hyperthermia, susceptibility to |
| RS118192170 | Drug Response | Uncertain significance; drug response | Central core myopathy, Malignant hyperthermia, susceptibility to |
| RS1003914966 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Central core myopathy, Congenital multicore myopathy with external ophthalmoplegia |
| RS1036598529 | Health Risk | Conflicting classifications of pathogenicity | Malignant hyperthermia, susceptibility to, 1 |
| RS1041327076 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS1053579438 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, RYR1-related myopathy, Malignant hyperthermia |
| RS1057518773 | Health Risk | Conflicting classifications of pathogenicity | Myopathy, RYR1-related disorder, Malignant hyperthermia |
| RS1057518970 | Health Risk | Conflicting classifications of pathogenicity | Respiratory insufficiency, Congenital muscular dystrophy, Myopathy |
| RS1057520588 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, RYR1-related disorder |
| RS1057523844 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS1064793932 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS1064797239 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS1064797242 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS1064797243 | Health Risk | Conflicting classifications of pathogenicity | Malignant hyperthermia, susceptibility to, 1 |
| RS111446464 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS111976711 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS111986316 | Health Risk | Conflicting classifications of pathogenicity | Malignant hyperthermia, susceptibility to, 1 |
| RS113058779 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Congenital multicore myopathy with external ophthalmoplegia, Congenital myopathy with fiber type disproportion |
| RS113460156 | Health Risk | Conflicting classifications of pathogenicity | Hypotonia, Malignant hyperthermia, susceptibility to |
| RS113928116 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS114009747 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Inborn genetic diseases, Malignant hyperthermia |
| RS114975624 | Health Risk | Conflicting classifications of pathogenicity | Congenital multicore myopathy with external ophthalmoplegia, Malignant hyperthermia, susceptibility to |
| RS1157851269 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, RYR1-related disorder |
| RS1168352165 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS1174927393 | Health Risk | Conflicting classifications of pathogenicity | RYR1-related disorder, Malignant hyperthermia, susceptibility to |
| RS1177353484 | Health Risk | Conflicting classifications of pathogenicity | Malignant hyperthermia, susceptibility to, 1 |
| RS118126378 | Health Risk | Conflicting classifications of pathogenicity | Malignant hyperthermia, susceptibility to, 1 |
| RS118192125 | Health Risk | Conflicting classifications of pathogenicity | Central core myopathy, RYR1-related disorder, Malignant hyperthermia |